Colorectal Cancer

Key Takeaways A new stool test that looks for signs of colon cancer was found to be more accurate than the existing test Nearly 2 million people a year are diagnosed with colon cancer, which is curable if detected early Developers say the new test is as easy to use as the current one Dutch...

A phase 1–2 clinical trial found that adagrasib combined with cetuximab in patients with KRAS G12C mutations can increase progression-free survival and overall survival in refractory colorectal cancer patients. There is a pressing need for effective treatments for metastatic colorectal cancer, particularly for patients with the KRAS G12C mutation, a kind of colorectal cancer that...

A phase 3 clinical trial confirms that combination therapy with trifluridine–tipiracil plus bevacizumab is associated with better clinical outcomes in refractory colorectal cancer cases than trifluridine–tipiracil monotherapy. First-line and second-line treatment of colorectal cancer includes chemotherapy with fluorouracil-based agents (oxaliplatin and irinotecan) along with newer vascular endothelial growth factor (VEGF)-based therapy (mainly bevacizumab) and epidermal...

Greater associations seen for those without colonoscopy screening, with smoking history, and for recent diabetes diagnosis   Type 2 diabetes is associated with an increased risk for colorectal cancer (CRC), with increased associations for those without colonoscopy screening and with smoking history, according to a study published online Nov. 14 in JAMA Network Open.  ...

This study reveals that obese individuals are 1.28 times more likely to develop right-sided colon cancer and highlights factors like age, sex, and race that influence this risk. Colorectal cancer (CRC) is among the most common cancer types in the United States and globally. There are two distinct types of CRC: right-sided colon cancer (RsCC)...

Cetuximab maintenance therapy for wild-type metastatic colorectal cancer is associated with clinically significant overall and progression-free survival. However, cetuximab therapy following FOLFIRI plus cetuximab is not appropriate for patients with mutated mitogen-activated protein kinase, warranting refined treatment strategies. There continues to be a lack of consensus regarding the best option among de-escalation modalities for managing...

A recent study found that elimination of race and ethnicity as risk predictors for colorectal recurrence is associated with worsened fairness of the risk prediction model, resulting in inappropriate care for ethnic and racial minorities in the population. The inclusion of racial and ethnic parameters in the risk prediction models is often inadequate, reflecting the...

Risk for death 3.49 times higher for those receiving no cancer treatment versus standard treatment or treatment with minor deviations. Fewer than one in 20 patients diagnosed with colorectal cancer (CRC) in Sub-Saharan Africa (SSA) receive guideline-concordant treatment, according to a study published in the September issue of the Journal of the National Comprehensive Cancer Network....

Cladosporium sp. was more commonly found in early-onset CRC, while Pseudomonas luteola, Ralstonia sp., Moraxella osloensis occurred more often in late-onset CRC. The microbiome (MB) of patients with colorectal cancer (CRC) varies between those diagnosed with early- or late-onset disease, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from June...